Enobosarm - Veru Healthcare
Alternative Names: GTx-024; MK-2866; Ostarine; S-22; VERU-024Latest Information Update: 30 Jun 2025
At a glance
- Originator Ohio State University Research Foundation; University of Tennessee Research Foundation
- Developer Oncternal Therapeutics, Inc.; Veru Healthcare
- Class Antineoplastics; Nitriles; Obesity therapies; Small molecules; Urologics
- Mechanism of Action Selective androgen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Breast cancer
- Phase II Obesity
- Preclinical Unspecified
- Discontinued Cachexia; Duchenne muscular dystrophy; Muscular atrophy; Urinary-Stress-Incontinence
Most Recent Events
- 24 Jun 2025 The US FDA grants a meeting to discuss the phase III trial for obesity
- 24 Jun 2025 Veru Healthcare plans a meeting with US FDA to discuss the phase III trial for obesity
- 24 Jun 2025 Efficacy and adverse event data from the maintenance extension portion of the phase IIb QUALITY trial in Obesity released by Veru Healthcare